Full-Time

Regional Marketer

Migraine

Axsome Therapeutics Inc

Axsome Therapeutics Inc

501-1,000 employees

Biopharmaceutical company developing CNS therapies

Compensation Overview

$160k - $190k/yr

+ Bonus + Equity

Los Angeles, CA, USA

In Person

West region includes WA, OR, CA, NV, ID, MT, WY, UT, AZ, HI; candidates must reside in the geography.

Category
Growth & Marketing (1)
Required Skills
Market Research
Marketing
Requirements
  • Bachelor’s degree (required); Graduate degree preferred
  • 8 years of pharmaceutical industry experience
  • 2 years of cross functional experience in at least 2 of the following areas: Field Sales, Field Sales Leadership, Product Marketing, Thought Leader Engagement, Key Account Management, Engagement with professional healthcare organizations
  • 50-75% travel, by air or car, regularly required
Responsibilities
  • Function as a thought leader liaison to key KOLs within the migraine community and build bridge to/from customer to Axsome Therapeutics
  • Develop and maintain KOL engagement plans and influence maps for thought leaders
  • Engage with KOLs at local, regional, and national congresses and advocacy events to discuss brand, disease state and commercial strategy as well as facilitate engagements and opportunities for executive leadership in support of marketing initiatives
  • Gather insights from key thought leaders to inform brand strategy and support development of content, tactics, and resources, when appropriate
  • Support cross-functional teams to gather key customer insights and input on the marketplace by garnering insights on commercial strategy, including designing local marketplace tactics, clinical messaging, access, and educational needs
  • Supporting the execution of approved Commercial Advisory Boards
  • Assist in identification of Healthcare Professional (HCP) consultants based on profile established by the approved Consultant Engagement Project Brief
  • Design, Facilitate, participate in, and attend advisory boards, where appropriate
  • Identify and develop HCP and access speakers to provide compliant, high-quality speaker programs on disease state, mechanism of disease, and product, when appropriate
  • Ensure appropriate and compliant execution of speaker programs
  • Monitor speaker performance at events and develops speakers to provide high quality promotional education through coaching as needed
  • Work with Marketing and contracted speakers to gain and synthesize feedback on current and future content development
Desired Qualifications
  • Demonstrated success and expertise with thought leader engagement, ad boards and speaker’s bureau- strongly preferred
  • Marketing, sales management, and/or extensive pharmaceutical product launch experience- strongly preferred
  • Proven ability to successfully manage accounts in a large geographical territory including both academic and community-based HCPs
  • Demonstrated ability to build productive stakeholder relationships internally and externally with impactful engagement tactics
  • Clinical knowledge and aptitude in complex/competitive disease states, preferably in the Migraine market.
  • Strong intellectual curiosity with a desire to continuously learn and improve by applying new knowledge and skills on the job and innovate with market dynamics
  • Highly collaborative with the ability to manage multiple projects simultaneously
  • Self-starter with strong organizational and planning skills. Able to determine effective approaches and take the appropriate action based on the available information/resources consistent with the over-arching strategy
  • Effective verbal and written communication skills
Axsome Therapeutics Inc

Axsome Therapeutics Inc

View

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders and focuses on research, development, and commercialization of medicines. Its lead product candidate, AXS-05, is an oral NMDA receptor antagonist being developed to treat major depressive disorder (MDD) and treatment-resistant depression (TRD). The company moves its pipeline through clinical trials and regulatory approvals to bring therapies to patients and earns revenue from drug sales, partnerships, and licensing. It differentiates itself by pursuing CNS-focused therapies with NMDA receptor targets and by pursuing designations like FDA Breakthrough Therapy to speed development, with a goal of improving patient outcomes and quality of life.

Company Size

501-1,000

Company Stage

IPO

Headquarters

New York City, New York

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • Auvelity Q1 2026 revenue hit $153.2M, up 59%, with $8B peak sales outlook post-Alzheimer's approval.
  • Total Q1 2026 revenue reached $191M, up 57%, beating estimates via sales force expansion.
  • Pipeline advances with AXS-12 NDA submission and AXS-20 addition for schizophrenia.

What critics are saying

  • Symbravo loses share to generic triptans and gepants due to high FDC pricing in 6-12 months.
  • AXS-12 NDA fails FDA approval from weak Phase III data, dropping stock 30-50% in 12-18 months.
  • Cash burns $305M reserves from sales force doubling before profitability in 18-24 months.

What makes Axsome Therapeutics Inc unique

  • Auvelity targets NMDA receptors for MDD and Alzheimer's agitation with FDA approvals.
  • Symbravo combines meloxicam-rizatriptan for acute migraine with long-term MOVEMENT trial benefits.
  • Sunosi treats narcolepsy daytime sleepiness with expanding Phase 3 indications.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company Equity

Company News

Yahoo Finance
Apr 8th, 2026
Axsome Therapeutics surges 33% annually since 2015 IPO, eyes $16B peak sales

Axsome Therapeutics, a midcap biotech, has delivered a compound annual growth rate of 33.32% since its 2015 IPO, potentially turning a $50,000 investment into nearly $1 million. However, replicating this performance over the next decade would require the company to reach a market capitalisation of approximately $157 billion. The company's 2025 revenue grew 66% year over year to $638.5 million, driven primarily by Auvelity, a depression treatment. Auvelity may soon receive approval for treating agitation in Alzheimer's disease, expanding its addressable market to over five million US patients. Axsome Therapeutics' pipeline includes several phase 3 assets targeting over 150 million patients, with predicted peak sales exceeding $16 billion. Whilst the company shows promise for long-term growth through the 2040s, matching its historical performance remains unlikely.

Bitget
Mar 18th, 2026
Superstring Capital invests $6.84M in CNS pharma Axsome Therapeutics, stock up 27%

Superstring Capital Management invested $6.84 million in Axsome Therapeutics, purchasing 37,433 shares during Q4 2025, according to a SEC filing dated 17 February 2026. The investment represents nearly 4% of the fund's reported 13F assets. Axsome Therapeutics, a clinical-stage biopharmaceutical company, develops treatments for central nervous system conditions including major depressive disorder, migraines and narcolepsy. The company has commercialised several treatments and recently launched a Phase 3 trial for solriamfetol in major depressive disorder with excessive daytime sleepiness. Axsome shares traded at $158.40 on Wednesday, up 27% over the past year, outpacing the S&P 500's 19% gain. The company reported $638.5 million in annual revenue, a 66% increase from 2024, with a market capitalisation of $8.1 billion.

Yahoo Finance
Mar 18th, 2026
Superstring Capital bets $6.8M on CNS drugmaker Axsome as Phase 3 trial begins and shares climb 27%

Superstring Capital Management has disclosed a new $6.84 million position in Axsome Therapeutics, acquiring 37,433 shares during the fourth quarter of 2025. The stake represents nearly 4% of the fund's assets under management. Axsome Therapeutics, a biopharmaceutical company specialising in central nervous system disorder treatments, has seen its shares rise 27% over the past year to $158.40. The company generated $638.5 million in revenue over the trailing twelve months, representing 66% growth from 2024. The company markets therapies for depression, migraine and sleep disorders whilst advancing a late-stage pipeline. Axsome recently initiated a Phase 3 trial for solriamfetol targeting major depressive disorder with excessive daytime sleepiness, a segment with no approved treatments currently available.

Yahoo Finance
Mar 12th, 2026
Axsome's Auvelity surpasses $500M revenue, eyes approval for Alzheimer's agitation by April

Axsome Therapeutics reported Auvelity surpassed $500 million in revenue during its third year, with total company sales approaching $640 million in 2025. Auvelity posted approximately 68% year-over-year growth. The company's supplemental NDA for AXS-05 (Auvelity) in Alzheimer's disease agitation is under priority review, with a PDUFA date of 30 April 2026. This represents Axsome's key near-term regulatory catalyst, supported by three positive trials. Axsome is doubling its field force from 300 to 600 representatives by Q2, ahead of a potential launch. The company is advancing seven Phase III trials across multiple indications whilst maintaining approximately $323 million in cash to fund operations.

Yahoo Finance
Mar 6th, 2026
Axsome doubles salesforce to 600 reps as AUVELITY hits $155M quarter ahead of April Alzheimer's decision

Axsome Therapeutics reported $155 million in quarterly revenue for AUVELITY, annualising over $600 million just 13 quarters post-launch, though market penetration remains at approximately 0.2% of the antidepressant market. The company plans to double its salesforce from 300 to 600 representatives to drive uptake and support a potential Alzheimer's agitation launch. Over 50% of AUVELITY prescriptions are now monotherapy, with roughly 15% first-line and 35% first-switch therapy. Primary care clinicians account for about 30% of prescribers. Axsome's supplemental NDA for AXS-05 in Alzheimer's disease agitation is under priority review with an FDA decision expected on 30 April. Management reported revenue growth outpacing operating expenses by 3-to-1 in 2025, demonstrating strong operating leverage despite increased direct-to-consumer spending.